Laboratory Corporation of America Holdings (NYSE:LH)‘s stock had its “buy” rating restated by equities research analysts at SunTrust Banks, Inc. in a report released on Thursday. They presently have a $190.00 target price on the medical research company’s stock. SunTrust Banks, Inc.’s price target suggests a potential upside of 26.45% from the company’s current price.

Several other equities research analysts have also commented on LH. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $170.00 price target for the company in a research note on Tuesday. Wells Fargo & Company began coverage on Laboratory Corporation of America Holdings in a research note on Thursday. They set an “outperform” rating and a $175.00 price target for the company. KeyCorp restated a “hold” rating on shares of Laboratory Corporation of America Holdings in a research note on Tuesday, September 26th. ValuEngine lowered Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Barclays PLC upped their price target on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $168.15.

Shares of Laboratory Corporation of America Holdings (NYSE LH) traded up 0.66% during trading on Thursday, reaching $150.26. 646,850 shares of the company’s stock traded hands. The stock has a market cap of $15.30 billion, a P/E ratio of 21.04 and a beta of 0.92. The company has a 50 day moving average price of $153.60 and a 200-day moving average price of $148.80. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.36 earnings per share. On average, equities research analysts expect that Laboratory Corporation of America Holdings will post $9.53 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Laboratory Corporation of America Holdings (LH) Earns Buy Rating from SunTrust Banks, Inc.” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/12/laboratory-corporation-of-america-holdings-lh-earns-buy-rating-from-suntrust-banks-inc.html.

In related news, insider Lisa J. Uthgenannt sold 5,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total value of $800,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Glenn A. Eisenberg sold 5,968 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total value of $951,657.28. Following the completion of the transaction, the chief financial officer now directly owns 18,122 shares of the company’s stock, valued at approximately $2,889,734.12. The disclosure for this sale can be found here. Insiders sold 222,968 shares of company stock valued at $34,980,922 in the last three months. 0.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Acrospire Investment Management LLC boosted its holdings in Laboratory Corporation of America Holdings by 16.5% in the second quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 100 shares during the last quarter. Sun Life Financial INC boosted its holdings in Laboratory Corporation of America Holdings by 9,200.0% in the second quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 736 shares during the last quarter. IFP Advisors Inc boosted its holdings in Laboratory Corporation of America Holdings by 83.9% in the second quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock valued at $177,000 after purchasing an additional 523 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Laboratory Corporation of America Holdings by 377.7% in the first quarter. Parallel Advisors LLC now owns 1,261 shares of the medical research company’s stock valued at $177,000 after purchasing an additional 997 shares during the last quarter. Finally, Hourglass Capital LLC purchased a new position in Laboratory Corporation of America Holdings in the second quarter valued at about $200,000. 93.19% of the stock is owned by hedge funds and other institutional investors.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.